Matthew C H Rohn1, Mary R Lee1, Samuel B Kleuter1, Melanie L Schwandt2, Daniel E Falk3, Lorenzo Leggio1,4. 1. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland. 2. Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. 3. Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland. 4. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: Alcoholism is a chronic relapsing disorder with complex behavioral and functional heterogeneity. To date, attempts to characterize subgroups of alcohol-dependent (AD) individuals have largely been focused on categorical distinctions based on behaviors such as ability to abstain, age of onset, and drinking motives, but these have failed to yield predictors of treatment response and disease course. The distinction between AD individuals who are or are not interested in treatment holds significant implications for interpreting results of human laboratory studies with nontreatment seekers and clinical trials with treatment-seeking AD patients. However, despite their crucial role in alcohol-related research, these 2 groups are poorly defined. In this exploratory analysis, we attempt to better define the phenotypic differences between these 2 experimentally relevant populations. METHODS: We analyzed data from AD individuals who participated in screening protocols to evaluate their suitability for participation in either treatment or nontreatment research studies at NIAAA. Scores on individual measures from a battery of behavioral, neuropsychological, and blood laboratory measures were compared between those who presented seeking treatment for AD and those who were not seeking treatment. Differences in each measure were assessed between the 2 groups. In addition, we explored whether significant differences were apparent when drinking behavior was used as a covariate. RESULTS: Treatment seekers manifested more impairment compared to nontreatment seekers on a wide variety of measures in the following categories: alcohol drinking, personality, impulsivity, trauma/stress, cognition, aggression, mood, and liver enzyme tests. Treatment seekers endorsed a greater number of AD criteria. Several measures including elevations in liver enzyme tests remained significantly different between the 2 groups when average daily alcohol consumption per drinking day was used as a covariate. CONCLUSIONS: Treatment-seeking, compared to nontreatment-seeking AD subjects who present for alcohol-related research studies, differ in characteristics beyond the quantity of alcohol consumption. Implications of these differences with respect to clinical research for treatments of AD are discussed. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Alcoholism is a chronic relapsing disorder with complex behavioral and functional heterogeneity. To date, attempts to characterize subgroups of alcohol-dependent (AD) individuals have largely been focused on categorical distinctions based on behaviors such as ability to abstain, age of onset, and drinking motives, but these have failed to yield predictors of treatment response and disease course. The distinction between AD individuals who are or are not interested in treatment holds significant implications for interpreting results of human laboratory studies with nontreatment seekers and clinical trials with treatment-seeking ADpatients. However, despite their crucial role in alcohol-related research, these 2 groups are poorly defined. In this exploratory analysis, we attempt to better define the phenotypic differences between these 2 experimentally relevant populations. METHODS: We analyzed data from AD individuals who participated in screening protocols to evaluate their suitability for participation in either treatment or nontreatment research studies at NIAAA. Scores on individual measures from a battery of behavioral, neuropsychological, and blood laboratory measures were compared between those who presented seeking treatment for AD and those who were not seeking treatment. Differences in each measure were assessed between the 2 groups. In addition, we explored whether significant differences were apparent when drinking behavior was used as a covariate. RESULTS: Treatment seekers manifested more impairment compared to nontreatment seekers on a wide variety of measures in the following categories: alcohol drinking, personality, impulsivity, trauma/stress, cognition, aggression, mood, and liver enzyme tests. Treatment seekers endorsed a greater number of AD criteria. Several measures including elevations in liver enzyme tests remained significantly different between the 2 groups when average daily alcohol consumption per drinking day was used as a covariate. CONCLUSIONS: Treatment-seeking, compared to nontreatment-seeking AD subjects who present for alcohol-related research studies, differ in characteristics beyond the quantity of alcohol consumption. Implications of these differences with respect to clinical research for treatments of AD are discussed. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Authors: R C Kessler; S Aguilar-Gaxiola; P A Berglund; J J Caraveo-Anduaga; D J DeWit; S F Greenfield; B Kolody; M Olfson; W A Vega Journal: Arch Gen Psychiatry Date: 2001-11
Authors: W R True; H Xian; J F Scherrer; P A Madden; K K Bucholz; A C Heath; S A Eisen; M J Lyons; J Goldberg; M Tsuang Journal: Arch Gen Psychiatry Date: 1999-07
Authors: Alexander McFarlane; Christopher R Clark; Richard A Bryant; Leanne M Williams; Raymond Niaura; Robert H Paul; Brian L Hitsman; Laura Stroud; David M Alexander; Evian Gordon Journal: J Integr Neurosci Date: 2005-03 Impact factor: 2.117
Authors: David P Bernstein; Judith A Stein; Michael D Newcomb; Edward Walker; David Pogge; Taruna Ahluvalia; John Stokes; Leonard Handelsman; Martha Medrano; David Desmond; William Zule Journal: Child Abuse Negl Date: 2003-02
Authors: Joseph P Schacht; Patrick K Randall; Patricia K Latham; Konstantin E Voronin; Sarah W Book; Hugh Myrick; Raymond F Anton Journal: Neuropsychopharmacology Date: 2017-04-14 Impact factor: 7.853
Authors: Lara A Ray; Spencer Bujarski; Megan M Yardley; Daniel J O Roche; Emily E Hartwell Journal: Am J Drug Alcohol Abuse Date: 2017-04-20 Impact factor: 3.829
Authors: Dylan K Richards; Osvaldo F Morera; José A Cabriales; Juliana Cardoso Smith; Craig A Field Journal: Alcohol Alcohol Date: 2020-06-25 Impact factor: 2.826
Authors: Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Jeanette M Tetrault; Julia Shi; Ralitza Gueorguieva; Brian Pittman; John H Krystal Journal: Neuropsychopharmacology Date: 2019-10-07 Impact factor: 7.853
Authors: Vanessa A Palzes; Andrea H Kline-Simon; Derek D Satre; Stacy Sterling; Constance Weisner; Felicia W Chi Journal: J Stud Alcohol Drugs Date: 2020-07 Impact factor: 2.582